TY - JOUR
T1 - Eco-, geno- and human toxicology of bio-active nanoparticles
for biomedical applications
AU - ROBBENS, J.
AU - VANPARYS, C.
AU - NOBELS, J.
AU - BLUST, R.
AU - VAN HOECKE, K.
AU - JANSSEN, C.
AU - DE SCHAMPHELAERE, K.
AU - Roland, Kathleen
AU - Blanchard, Gersande
AU - Silvestre, Frederic
AU - Gillardin, Virginie
AU - Kestemont, Patrick
AU - ANTONISSEN, R.
AU - Toussaint, Olivier
AU - Saout, Christelle
AU - Vankoningsloo, Sebastien
AU - ALFARO-MORENO, E.
AU - HOE, P.
AU - GONZALES, L.
AU - DUBRUEL, P.
AU - TROISFONTAINE, P.
PY - 2010
Y1 - 2010
N2 - Gene delivery has become an increasingly important strategy for treating a variety of human diseases,
including infections, genetic disorders and tumours. To avoid the difficulties of using viral carriers, more
and more non-viral gene delivery nanoparticles are developed. Among these new approaches polyethylene
imine (PEI) is currently considered as one of the most effective polymer based method solution and
considered as the gold standard.
The toxicity of nanoparticles is a major concern when used for medical application. In this study we
chose two nanoparticles for an in depth toxicological and ecotoxicological evaluation, one well characterized,
PEI, and another novel polymer, poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA). In the
present study we have assessed the toxicity of these cation nanoparticles as such and of the polyplexes
- nanoparticles covered with DNA. As these nanoparticles are also frequently used in high volumes in
various industries and as such may enter in the environment, we also made an initial assessment of
ecotoxicological effects assessment.
The following nanoparticles related aspects have been studied during the project: development and
characterization, ecotoxicity, general toxicity and specific toxicity. To this end a battery of different tests
was used. The conclusion of these tests is that toxicity is varying between different nanoparticles and
between different DNA covering ratios. In general, in the different systems tested, the PEI polymer is
more toxic than thePDMAEMApolymer. The same difference is seen for the polyplexes and the higher the
charge ratio, the more toxic are the polyplexes. Our study also clearly shows the need for a broad spectrum
of toxicity assays for a comprehensive risk assessment. Our study has performed such a comprehensive
analysis of two biomedical nanoparticles.
AB - Gene delivery has become an increasingly important strategy for treating a variety of human diseases,
including infections, genetic disorders and tumours. To avoid the difficulties of using viral carriers, more
and more non-viral gene delivery nanoparticles are developed. Among these new approaches polyethylene
imine (PEI) is currently considered as one of the most effective polymer based method solution and
considered as the gold standard.
The toxicity of nanoparticles is a major concern when used for medical application. In this study we
chose two nanoparticles for an in depth toxicological and ecotoxicological evaluation, one well characterized,
PEI, and another novel polymer, poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA). In the
present study we have assessed the toxicity of these cation nanoparticles as such and of the polyplexes
- nanoparticles covered with DNA. As these nanoparticles are also frequently used in high volumes in
various industries and as such may enter in the environment, we also made an initial assessment of
ecotoxicological effects assessment.
The following nanoparticles related aspects have been studied during the project: development and
characterization, ecotoxicity, general toxicity and specific toxicity. To this end a battery of different tests
was used. The conclusion of these tests is that toxicity is varying between different nanoparticles and
between different DNA covering ratios. In general, in the different systems tested, the PEI polymer is
more toxic than thePDMAEMApolymer. The same difference is seen for the polyplexes and the higher the
charge ratio, the more toxic are the polyplexes. Our study also clearly shows the need for a broad spectrum
of toxicity assays for a comprehensive risk assessment. Our study has performed such a comprehensive
analysis of two biomedical nanoparticles.
KW - Biomedical nanoparticle
KW - Specific toxicity
KW - General toxicity
KW - PEI and PDMAEMA
KW - Toxicity
U2 - 10.1016/j.tox.2009.11.002
DO - 10.1016/j.tox.2009.11.002
M3 - Article
SN - 0300-483X
VL - 269
SP - 170
EP - 181
JO - Toxicology
JF - Toxicology
ER -